KWM
AXSM icon

Kingsview Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Kingsview Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305K Buy
+1,806
New +$312K ﹤0.01% 1080

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kingsview Wealth Management's AXSM Position: Q1 2026 in Review

Kingsview Wealth Management opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 1,806 shares worth $305K. The stake represents ﹤0.01% of the portfolio and ranks #1080 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Kingsview Wealth Management held 1,806 shares of Axsome Therapeutics worth $305K as of Q1 2026.
  • Axsome Therapeutics was a new Kingsview Wealth Management position in Q1 2026.
  • Axsome Therapeutics made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q1 2026, its #1080 holding.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.